- Home
- SYBX
SYBX
Synlogic Inc.
as 02-21-2025 4:00pm EST
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WINCHESTER |
| Market Cap: | 16.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 18.8K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.22 - $2.04 | Next Earning Date: | 03-18-2025 |
| Revenue: | $2,777,000 | Revenue Growth: | 292.23% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Synlogic Inc. (SYBX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dooley Mary Beth | SYBX | See Remarks below | Feb 3 '25 | Sell | $1.33 | 2,107 | $2,802.31 | 13,045 |
Latest Synlogic Inc. News
SYBX Breaking Stock News: Dive into SYBX Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 months ago
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)
GlobeNewswire
3 months ago
Synlogic Reports Third Quarter 2024 Financial Results
Clinical Trials Arena
6 months ago
Otsuka snaps up Jnana with its phenylketonuria drug for $800m
GlobeNewswire
6 months ago
Synlogic Reports Second Quarter 2024 Financial Results
Pharmaceutical Technology
7 months ago
Otsuka snaps up Jnana with its phenylketonuria drug for $800m
GlobeNewswire
9 months ago
Synlogic Reports First Quarter 2024 Financial Results
Simply Wall St.
9 months ago
We Think Synlogic (NASDAQ:SYBX) Needs To Drive Business Growth Carefully
Zacks
a year ago
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Compare SYBX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYBX Synlogic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.